Treatment for Haemophilus influenzae Infections

First-line Treatment Options

The American Academy of Pediatrics recommends high-dose amoxicillin-clavulanate as first-line therapy for non-severe Haemophilus influenzae infections due to increasing prevalence of β-lactamase-producing strains 1, 3
The preferred ratio of amoxicillin to clavulanate is 14:1 to minimize gastrointestinal side effects while maintaining efficacy 1
For patients with penicillin allergy, the European Respiratory Society suggests alternatives such as cefdinir or macrolides in areas with low resistance rates 1, 2

For community-acquired pneumonia or bronchitis where H. influenzae is suspected, the Infectious Diseases Society of America recommends high-dose amoxicillin-clavulanate or a respiratory fluoroquinolone for outpatient treatment, and ceftriaxone, cefotaxime, or IV amoxicillin-clavulanate for hospitalized patients 2, 5, 6
The British Thoracic Society suggests a treatment duration of at least 7 days for non-severe infections and 10-14 days for severe infections 6

The American Academy of Pediatrics notes that 58-82% of H. influenzae isolates are susceptible to amoxicillin, meaning 18-42% produce β-lactamase, and recommends using β-lactamase-stable antibiotics in areas with high rates of β-lactamase-producing H. influenzae 1, 2, 4
If no improvement after 48-72 hours of initial therapy, the European Respiratory Society suggests switching to ceftriaxone or adding a macrolide if atypical pathogens are suspected 1, 6